《哈门那公司HUMANA（HUM）2023年年度报告「NYSE」（英文版）（218页）.pdf》由会员分享，可在线阅读，更多相关《哈门那公司HUMANA（HUM）2023年年度报告「NYSE」（英文版）（218页）.pdf（218页珍藏版）》请在三个皮匠报告上搜索。

1、Annual Report AnnualReport1Humana Inc.financial highlights Dollars in millions,except per common share results Generally Accepted Accounting Principles(GAAP)2023 2022 2021 2020 2019 OPERATING RESULTS Revenues$106,374$92,870$83,064$77,155$64,888 Net income attributable to Humana$2,489$2,806$2,933$3,3

2、67$2,707 Diluted earnings per common share$20.00$22.08$22.67$25.31$20.10 FINANCIAL POSITION Total assets$47,065$43,055$44,358$34,969$29,074 Total liabilities$30,747$27,685$28,255$21,241$17,037 Total stockholders equity$16,318$15,370$16,103$13,728$12,037 Cash flows from operations$3,981$4,587$2,262$5

3、,639$5,284 MEMBERSHIP(IN THOUSANDS)Consolidated medical membership 16,857.8 17,079.2 17,067.0 16,831.6 16,667.2 Consolidated specialty membership 4,868.3 5,194.8 5,294.3 5,310.3 5,425.9 1 Dear fellow stockholders,was a dynamic and challenging year as the Medicare Advantage(MA)industry faced a signif

4、icant and unanticipated increase in medical cost trends throughout the year.We worked hard to offset the higher than anticipated medical costs through areas such as administrative cost containment and productivity initiatives,as well as other business outperformance.We take our commitments seriously

5、 and are disappointed we were unable to fully offset the further increase in cost trends experienced in the fourth quarter,despite our best efforts to identify mitigation opportunities throughout the year,resulting in lower than anticipated earnings growth for 2023.While not minimizing the significa

6、nce of those challenges,we are proud of the strong growth we achieved in our individual MA,Medicaid and CenterWell businesses and the progress made across the enterprise to advance our industry-leading MA and senior-focused value-based care platforms,supported by the unwavering commitment of our ove